retatrutide trial results news today Lilly's triple agonist delivers up to 71.2 lbs of weight loss Triple hormone receptor agonist retatrutide

The development of GLP-1 medicines has transformed the therapeutic options for patients with type 2 diabetes (T2D) who are unable to achieve sufficient glucose control with existing treatments

Sarah Eby, a sports medicine physician at Mass General Brigham and assistant professor of physical medicine and rehabilitation at Harvard Medical School

In the HARMONY trial the effect of albiglutide in patients on an SGLT-2 inhibitor on cardiovascular death, myocardial infarction, or stroke was similar

The GLP-1RAs are achieving blockbuster status, meaning a drug that generates yearly sales exceeding one billion dollars for a drug company

There is no one size fits all approach to weight in midlife

Wang Y, Liu Q, Kang SG, Huang K, Tong T